Biomarkers Consortium

Icon steps up for patient-reported outcome measure endpoint validation

Monday, February 27, 2017

The FDA has chosen Icon to create industry-standard patient-reported outcome (PRO) measures and to validate those endpoints for antibacterial drug trials. Partnering on the initiative with Icon is the Biomarkers Consortium and the Foundation of the National Institutes of Health (FNIH). Also involved is the Infectious Diseases Society of America and the National Institute of Allergy and Infectious Diseases.

[Read More]

New presurgery combination therapy for triple-negative breast cancer

Tuesday, December 17, 2013

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer.

[Read More]